Alligator Bioscience has entered into an evaluation and option agreement with a company specializing in infectious diseases regarding the company's bispecific antibody format RUBY. The agreement includes a two-year evaluation period and gives the counterparty an exclusive option to negotiate a license agreement. An option fee of USD 75 will be paid to Alligator in installments. CEO Soren Bregenholt sees the agreement as an example of how the company's innovative power can generate external financing.
|
Published September 3, 2025
Alligator signs option agreement for RUBY platform
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account